2020
The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial
Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS, Diamond MP, Krawetz SA, Usadi R, Baker VL, Coward RM, Huang H, Wild R, Masson P, Smith JF, Santoro N, Eisenberg E, Zhang H, Network R. The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility And Sterility 2020, 113: 552-560.e3. PMID: 32111479, PMCID: PMC7219515, DOI: 10.1016/j.fertnstert.2019.11.008.Peer-Reviewed Original ResearchConceptsMonths of treatmentMale factor infertilityFactor infertilityLive birthsSemen parametersPlacebo groupPrimary outcomeSperm concentrationPlacebo-controlled trialLive birth rateCumulative live birthDNA fragmentationFemale partnersSperm DNA fragmentation indexLycopene dailyVivo pregnancyClomiphene citrateSecondary outcomesEntire cohortAsthenospermic menFertility centerIntrauterine inseminationMonth 4Tubal patencyClinical trials
2014
Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. New England Journal Of Medicine 2014, 371: 119-129. PMID: 25006718, PMCID: PMC4175743, DOI: 10.1056/nejmoa1313517.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvary syndromeCongenital anomaliesLive birthsHigh incidenceOvulation rateSignificant between-group differencesCumulative ovulation rateNormal uterine cavityOverall congenital anomaliesBetter pregnancy outcomesPatent fallopian tubesCumulative live birthMajor congenital anomaliesBetween-group differencesYears of ageClomiphene groupLetrozole groupRotterdam criteriaAdverse eventsHot flushesPregnancy outcomesInfertile womenMulticenter trialPrimary outcome